Literature DB >> 8626375

Human native soluble CD40L is a biologically active trimer, processed inside microsomes.

F Pietravalle1, S Lecoanet-Henchoz, H Blasey, J P Aubry, G Elson, M D Edgerton, J Y Bonnefoy, J F Gauchat.   

Abstract

CD40 ligand (CD40L) is a glycoprotein expressed on the surface of activated helper T cells, basophils, mast cells, and eosinophils. Binding of CD40L to its receptor CD40 on the B cell surface induces B cell proliferation, adhesion, and immunoglobulin class switching. We have identified soluble cleavage products of human CD40L in the supernatant of a stimulated human T cell clone. Subcellular fractionation experiments have shown that the transmembrane CD40L is processed inside the microsomes and that its cleavage is stimulation-dependent. The native human soluble CD40L is trimeric and, when used in conjunction with interleukin-4, induces B cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8626375     DOI: 10.1074/jbc.271.11.5965

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

Review 1.  The CD40/CD40L costimulatory pathway in inflammatory bowel disease.

Authors:  S Danese; M Sans; C Fiocchi
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

2.  Expression and purification of soluble murine CD40L monomers and polymers in yeast Pichia pastoris.

Authors:  Christina E Hermanrud; Carrie L Lucas; Megan Sykes; Christene A Huang; Zhirui Wang
Journal:  Protein Expr Purif       Date:  2010-11-11       Impact factor: 1.650

3.  Impaired NFAT and NFκB activation are involved in suppression of CD40 ligand expression by Δ(9)-tetrahydrocannabinol in human CD4(+) T cells.

Authors:  Thitirat Ngaotepprutaram; Barbara L F Kaplan; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2013-08-30       Impact factor: 4.219

4.  Complement-induced regulatory T cells suppress T-cell responses but allow for dendritic-cell maturation.

Authors:  Winfried Barchet; Jeffrey D Price; Marina Cella; Marco Colonna; Sandra K MacMillan; J Perren Cobb; Paul A Thompson; Kenneth M Murphy; John P Atkinson; Claudia Kemper
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

5.  Platelet-derived or soluble CD154 induces vascularized allograft rejection independent of cell-bound CD154.

Authors:  He Xu; Xiaojie Zhang; Roslyn B Mannon; Allan D Kirk
Journal:  J Clin Invest       Date:  2006-02-23       Impact factor: 14.808

6.  Reduction of CD1d expression in vivo minimally affects NKT-enhanced antibody production but boosts B-cell memory.

Authors:  Gillian A Lang; Amy M Johnson; T Scott Devera; Sunil K Joshi; Mark L Lang
Journal:  Int Immunol       Date:  2011-03-12       Impact factor: 4.823

7.  Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.

Authors:  Jianping Huang; Caroline Jochems; Tara Talaie; Austin Anderson; Alessandra Jales; Kwong Y Tsang; Ravi A Madan; James L Gulley; Jeffrey Schlom
Journal:  Blood       Date:  2012-08-28       Impact factor: 22.113

8.  Nondepleting anti-CD40-based therapy prolongs allograft survival in nonhuman primates.

Authors:  I R Badell; P W Thompson; A P Turner; M C Russell; J G Avila; J A Cano; J M Robertson; F V Leopardi; E A Strobert; N N Iwakoshi; K A Reimann; M L Ford; A D Kirk; C P Larsen
Journal:  Am J Transplant       Date:  2011-09-15       Impact factor: 8.086

9.  Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.

Authors:  S Danese; J A Katz; S Saibeni; A Papa; A Gasbarrini; M Vecchi; C Fiocchi
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

10.  Soluble CD40 ligand induces beta3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling.

Authors:  K S Srinivasa Prasad; Patrick Andre; Ming He; Ming Bao; Jeanne Manganello; David R Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.